MARKETSnap
  • Market Snapshots
    • Gainers & Losers
    • Most Active & More
    • 52-Week High/Low
    • Dividends
    • P/E Ratios
      • Large Caps
      • Absolute
      • Total Market PE
    • Stocks Performance
      • Large Caps
      • Absolute
    • Industries Performance
      • Industry
      • Sector
  • Analyze Stock
    • Analyze a stockAnalyze ABBV →
    • FindStock Picks / Stock Screener
    • Value · ABBVIntrinsic Value Calculator
    • Invest · ABBVInvestment Case
    • Hold · ABBV5-Year Outlook
  • Learn
  • Calendar
  • Investment Compounding
    Calculator
  • Investing Philosophy
  • More
    • Charts
    • Commodities
    • Currencies
    • Economic Indicators
      • Inflation
      • Consumer Sentiment
      • Recession Probability
      • Treasury Rates
      • GDP
ABBV stock logo

ABBV

AbbVie Inc.

$295.03
0.58
 (0.2%)
Exchange:  NYSE
Market Cap:  521.5B
Shares Outstanding:  1.774B
Delayed data
Overview
Earnings
Financials
Valuation
Chart

About The Company

Sector:  HealthcareView sector performance
Industry:  Drug Manufacturers – GeneralView industry performance
   
CEO:  Robert A. Michael
Full Time Employees:  57000
Address: 
1 North Waukegan Road
North Chicago
IL
60064-6400
US
Website:  https://www.abbvie.com
AbbVie Inc. is a global biopharmaceutical company dedicated to the discovery, development, manufacturing, and commercialization of advanced medicines. Its extensive therapeutic portfolio encompasses several key areas: Immunology and Inflammation: Leading products include HUMIRA, an injectable therapy for autoimmune and intestinal Behçet’s diseases; SKYRIZI, which addresses moderate to severe plaque psoriasis in adults; and RINVOQ, a JAK inhibitor for moderate to severe active rheumatoid arthritis in adult patients. Oncology and Hematology: For blood cancers, AbbVie provides IMBRUVICA and VENCLEXTA (a BCL-2 inhibitor), both indicated for adult patients with chronic lymphocytic leukemia (CLL) and small lymphocytic lymphoma (SLL). Virology: MAVYRET offers a treatment option for individuals with chronic HCV genotype 1-6 infection. Gastroenterology and Endocrinology: The company supplies CREON, an enzyme replacement therapy for exocrine pancreatic insufficiency, and Synthroid, used to manage hypothyroidism. Linzess/Constella helps treat irritable bowel syndrome with constipation (IBS-C) and chronic idiopathic constipation. Women’s Health and Urology: Lupron serves as a palliative treatment for conditions like advanced prostate cancer, endometriosis, central precocious puberty, and anemia caused by uterine fibroids. ORILISSA, a nonpeptide small molecule GnRH antagonist, is designed for women experiencing moderate to severe endometriosis pain. Neurology: AbbVie offers Duopa and Duodopa, a levodopa-carbidopa intestinal gel for Parkinson’s disease, and Ubrelvy to treat migraines (with or without aura) in adults. The therapeutic formulation of Botox is also part of its offerings. Ophthalmology: Its eye care segment features Lumigan/Ganfort (a bimatoprost ophthalmic solution) and Alphagan/Combigan (an alpha-adrenergic receptor agonist), both aimed at reducing elevated intraocular pressure (IOP) in patients with open-angle glaucoma (OAG) or ocular hypertension. Restasis, a calcineurin inhibitor immunosuppressant, is provided to enhance tear production, alongside other specialized eye care products. AbbVie Inc. also engages in research collaborations, including a partnership with Dragonfly Therapeutics, Inc. The company was founded in 2012 and operates from its headquarters in North Chicago, Illinois.

Click to read more…

Revenue Segmentation

Revenue by type

Revenue by region

Log in to continue

Log in to see the complete revenue and geographic breakdown.

Log in — it's free

ABBV full analysis

01/11/2026

Welcome back to MarketSnap. Let's start with Friday's session, because it tells you almost everything you need to know about the mood. The Nasdaq fell nearly 3%. Tech got hit for over 4%. And healthcare? Healthcare finished higher. Money is running from AI and hiding somewhere boring. And one of the places it's hiding is AbbVie — a Dividend King with a beta around 0.28, up roughly 40% in six months and 29% in a year, far ahead of its…

Listen to full analysis (audio file)

Open in MarketSnap Listen

Log in to continue

Log in to see the full analysis preview and audio links.

Log in — it's free

Industry Peers

TICKERCOMPANYMKT CAPP/EFWD P/EROIC
ABABBV logoABBVAbbVie Inc.521.5B50.621.116.6%
MRMRK logoMRKMerck & Co., Inc.364.3B14953.24.4%
JNJNJ logoJNJJohnson & Johnson687.9B43.325.715.0%
NVNVS logoNVSNovartis AG303.1B30.818.014.0%
AZAZN logoAZNAstraZeneca PLC286.1B25.918.013.1%
AMAMGN logoAMGNAmgen Inc.251.9B26.819.815.6%

EPS

Historical EPS and analyst estimates in one chart. Log in for the full interactive view and links to detailed estimates.

Log in to continue

Log in for the full EPS chart and links to analyst estimates.

Log in — it's free
View full analyst estimates

Earnings Call

Full text

Earnings transcript

Read the complete earnings call transcript.

AI summary

Key takeaways

Short, structured highlights from the call so you can focus on what matters.

2026/10/30 — 3 quarter 2026

Log in to continue

Log in to read the full transcript and AI-generated earnings summaries.

Log in — it's free
Income Statement
Balance Sheet
Cash Flow Statement
Analyst Estimates

Income Statement

Year202320242025
Revenue54,318,00056,334,00061,160,000
Gross Profit33,903,00039,430,00042,956,000
EBITDA17,172,00014,910,00017,629,000
Operating Income12,757,0009,137,00020,091,000
Net Income4,863,0004,278,0004,226,000

Log in to continue

Log in to see the income statement and 10 historical years.

Log in — it's free

(* All numbers are in thousands)

Balance Sheet

Year202320242025
Total Assets134,711,000135,161,0000
Total Liabilities124,314,000131,797,0002,599,000
Total Stockholders Equity10,360,0003,325,000-2,599,000
Total Debt60,120,00067,841,0000
Cash and Cash Equivalents12,814,0005,524,0000

Log in to continue

Log in to see the balance sheet and 10 historical years.

Log in — it's free

(* All numbers are in thousands)

Cash Flow Statement

Year202320242025
Operating Cash Flow22,839,00018,806,0000
Capital Expenditure-777,000-974,0000
Free Cash Flow22,062,00017,832,0000
Net Income4,820,0004,286,0004,226,000
Net Change in Cash3,613,000-7,290,000-5,524,000

Log in to continue

Log in to see the cash flow statement and 10 historical years.

Log in — it's free

(* All numbers are in thousands)

Analyst Estimates

Fiscal Year2030Research AccessResearch AccessResearch AccessResearch Access
Estimated Revenue (Low)84,530,253.599Research AccessResearch AccessResearch AccessResearch Access
Estimated Revenue (High)87,953,838.680Research AccessResearch AccessResearch AccessResearch Access
Estimated Revenue (Avg)86,266,571.429Research AccessResearch AccessResearch AccessResearch Access
Estimated Ebitda (Low)49,737,708.264Research AccessResearch AccessResearch AccessResearch Access
Estimated Ebitda (High)52,047,187.954Research AccessResearch AccessResearch AccessResearch Access
Estimated Ebitda (Avg)50,908,999.190Research AccessResearch AccessResearch AccessResearch Access
Estimated Net Income (Low)36,491,712.220Research AccessResearch AccessResearch AccessResearch Access
Estimated Net Income (High)38,424,981.941Research AccessResearch AccessResearch AccessResearch Access
Estimated Net Income (Avg)37,472,202.021Research AccessResearch AccessResearch AccessResearch Access
Estimated SGA Expense (Low)20,465,051.785Research AccessResearch AccessResearch AccessResearch Access
Estimated SGA Expense (High)21,293,912.968Research AccessResearch AccessResearch AccessResearch Access
Estimated SGA Expense (Avg)20,885,420.029Research AccessResearch AccessResearch AccessResearch Access
Estimated EPS (Avg)21.120Research AccessResearch AccessResearch AccessResearch Access
Estimated EPS (High)21.660Research AccessResearch AccessResearch AccessResearch Access
Estimated EPS (Low)20.570Research AccessResearch AccessResearch AccessResearch Access
Number of Analysts (Estimated Revenue)11Research AccessResearch AccessResearch AccessResearch Access
Number of Analysts (Estimated EPS)3Research AccessResearch AccessResearch AccessResearch Access

Log in to continue

Log in with Research Access to see up to 5 years of analyst estimates.

Create a free account

(* All numbers are in thousands)

Current Key Metrics

?Revenue
 (TTM)
: 
56.334B  ?P/S
 (TTM)
: 
7.9
?Net Income
 (TTM)
: 
4.238B  ?P/E
 (TTM)
: 
50.61
?Enterprise Value
 (TTM)
: 
591.629B  ?EV/FCF
 (TTM)
: 
31.35
?Dividend Yield
 (TTM)
: 
2.35%  ?Payout Ratio
 (TTM)
: 
117.32%
?ROE
 (TTM)
: 
-202.43%  ?ROIC
 (TTM)
: 
16.57%
?Net Debt
 (TTM)
: 
62.286B  ?Debt/Equity
 (TTM)
: 
-17.65
?P/B
 (TTM)
: 
-114.07  ?Current Ratio
 (TTM)
: 
0.87

Log in to continue

Log in to see all key valuation metrics and ratios for this symbol.

Log in — it's free

Forward P/E Ratios

?

Forward P/E (Avg EPS estimate) — log in with Research Access for high/low estimates and the interactive table.

Forward P/E 1YResearch AccessResearch AccessResearch AccessResearch Access
21.07Research AccessResearch AccessResearch AccessResearch Access

Log in to continue

Log in with Research Access for forward P/E high/low estimates and the full multi-year table.

Create a free account

SWOT Analysis

Strengths (preview)

  • Accelerating top- and bottom-line momentum: Q3 2026 revenue of $17.4B grew 10.3% YoY and beat consensus by ~$200M; non-GAAP EPS of $3.82 beat the $3.74 estimate and rose 105.4% YoY (vs. $1.86 prior year). Full-year revenue guidance was raised by $200M (cumulative $800M increase since start of year) and the 2026 EPS outlook was lifted, with management guiding to "top-tier growth next year."
  • Durable immunology franchise offsetting Humira erosion: Skyrizi generated $17.56B in FY2025 revenue and posted 22.7% YoY growth in Q3 2026 ($5.78B); Rinvoq contributed $8.30B in FY2025. Combined Skyrizi/Rinvoq growth of ~$6B is expected this year, with Humira down 30.6% but still contributing $4.54B in FY2025—evidence of a successful patent-cliff transition.
  • High-margin, cash-generative model with low volatility: Gross margin TTM of 76.3%, ROIC TTM of 18.6%, and free cash flow of $17.8B in FY2024. Beta of 0.281 and a 2.35% dividend yield (with a 5.2% dividend increase announced, effective February 2027) support the stock's Dividend King status and defensive profile.

Log in with Research Access for Weaknesses, Opportunities, Threats, and the complete SWOT.

Log in to continue

Log in with Research Access for the complete SWOT analysis.

Create a free account

At what price to buy it? -
Intrinsic Value Calculator

Based on current fundamentals and analyst forecasts, MarketSnap estimates ABBV intrinsic value between $282.22 – $500.62 per share. This depends on revenue growth, margins, and discount rate.

This is an automatic estimate. The most reliable way to know fair value for your own assumptions is to run the calculator below.


Calculate ABBV Intrinsic Value

Common questions about ABBV valuation

Is AbbVie Inc. (ABBV) overvalued or undervalued right now?

MarketSnap estimates intrinsic value for AbbVie Inc. (ABBV) using its proprietary valuation methodology, which incorporates discounted cash flow (DCF) analysis together with long-term earnings and fundamentals assumptions. By comparing intrinsic value to the current market price, long-term investors can see whether the stock screens as potentially overvalued, fairly valued, or undervalued today.

Is ABBV a buy, hold, or sell for long-term investors?

MarketSnap does not give one-word “buy” or “sell” calls. Instead, it shows whether ABBV trades at a premium or discount to its estimated intrinsic value, how sensitive that value is to growth and margin assumptions, and how the stock fits into a diversified, long-term portfolio so investors can make their own buy, hold, or sell decision.

What is ABBV’s P/E ratio?

You can see ABBV’s trailing P/E (TTM) and forward P/E estimates in the Current Key Metrics and Forward P/E Ratios sections above. The P/E ratio compares the current share price to earnings per share and helps investors gauge valuation relative to earnings.

How is intrinsic value calculated for ABBV?

MarketSnap uses its own valuation framework—not a generic spreadsheet DCF alone. Future cash flows and earnings are projected, discounted, and combined with MarketSnap’s methodology so intrinsic value reflects fundamentals and long-term assumptions. You can run your own inputs and see the result using the Intrinsic Value Calculator above.

Is ABBV a good long-term investment?

Whether ABBV fits a long-term portfolio depends on your assumptions about growth, margins, and risk. MarketSnap provides the metrics, intrinsic value calculator, and SWOT context so you can form your own view rather than rely on a single buy/sell rating.

Research tools for AbbVie Inc.

  • AbbVie Inc. intrinsic value calculatorEstimate what the business is worth
  • AbbVie Inc. 5-year outlookWhat has to go right, and what could go wrong
ABBV

1-day price chart preview. Log in for 1W through 5Y ranges and period tabs.

Daily snapshot

0.2
MarketSnap

Trading Metrics:

Open: 296.58   Previous Close: 294.45
Day Low: 293.56   Day High: 297.25
Year Low: 190.75   Year High: 302.93
Price Avg 50: 274.81   Price Avg 200: 240.41
Volume: 3.26M   Average Volume: 5.004M

Log in to continue

Log in for multi-period charts (1W–5Y), period tabs, and the same layout as members.

Log in — it's free
See in Nexus

Relevant news

3 Dividend Stocks Built for a Market Priced Like It's 1999
13-11-2026 04:44
3 Dividend Stocks Built for a Market Priced Like It's 1999
How Did AbbVie's Immunology Franchise Fare in Q3?
12-11-2026 14:01
How Did AbbVie's Immunology Franchise Fare in Q3?
AbbVie Inc. $ABBV Stock Bought by AlphaCore Capital LLC
10-11-2026 03:53
AbbVie Inc. $ABBV Stock Bought by AlphaCore Capital LLC
Is Trending Stock AbbVie Inc. (ABBV) a Buy Now?
04-11-2026 10:01
Is Trending Stock AbbVie Inc. (ABBV) a Buy Now?
AbbVie's Humira Era Is Fading, But Its New Growth Engines Face Another Test
02-11-2026 13:16
AbbVie's Humira Era Is Fading, But Its New Growth Engines Face Another Test
Prediction: AbbVie's Next Blockbuster Is Hiding in a Two-Drug Crohn's Combo
02-11-2026 05:25
Prediction: AbbVie's Next Blockbuster Is Hiding in a Two-Drug Crohn's Combo

DISCLAIMER: The stock market data provided on this website is for informational purposes only and is not intended for trading purposes. While we strive to provide accurate and timely information, we cannot guarantee that the information is accurate at the moment it is received or that it will continue to be accurate in the future. We are not responsible for any actions taken based on the information provided on this website. Always consult with a licensed financial professional before making any investment decisions.
Terms of Service

Copyright © 2025 MarketSnap. All rights reserved.

How MarketSnap works

What’s new

Contact Us

Privacy Policy

Cookie Policy

Terms of Service

Hover Image
MARKETSnap

Market

🇺🇸 United States

Language

    • Gainers & Losers
    • Most Active & More
    • 52-Week High/Low
    • Dividends
      • Large Caps
      • Absolute
      • Total Market PE
      • Large Caps
      • Absolute
      • Industry
      • Sector
    • Analyze a stockAnalyze ABBV →
    • FindStock Picks / Stock Screener
    • Value · ABBVIntrinsic Value Calculator
    • Invest · ABBVInvestment Case
    • Hold · ABBV5-Year Outlook
  • Learn
  • Calendar
  • Investment Compounding Calculator
    • Charts
    • Commodities
    • Currencies
      • Inflation
      • Consumer Sentiment
      • Recession Probability
      • Treasury Rates
      • GDP
  • Investing Philosophy
  • Nexus
    • Recent Activity
      • Overview
      • My Valuations
      • My Investment Journal
      • Watchlists & Portfolio
    • Settings
    • Public profile ↗
  • Log in

Media

Watch Listen Read
Ask MarketSnap AI

MarketSnap AI Assistant

Uses MarketSnap data and this page

Ready

🔒 You are currently logged out

Login

It's free

MarketSnap Assistant · Tips
    MarketSnap

    Welcome to MarketSnap

    The AI-powered workspace for stock pickers.

    Continue with Google Continue with email

    Already a member? Sign in

    Find stocks·Value them·Build the case·Journal decisions·Track what changes

    Free to join. No card needed. Privacy Policy

    Create your free MarketSnap account Continue with Google
    Chat with us MarketSnap support · account, plans, settings, help
    How MarketSnap works

    The conversation above goes to the MarketSnap team with your message. We reply by e-mail.